This article is part of a Chronicle. See more from this Chronicle
Richard Gilbert, Jul 12, 2008
The U.S. Federal Trade Commission alleged adverse effects on innovation in about forty percent of all merger challenges between 1996 and mid-2008. The percentage was much higher for challenges in industries with unusually high research and development intensity, such as pharmaceuticals (excluding generics), chemicals, software, instruments, high-tech manufacturing, defense, and aerospace. The FTC chal
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.17.150.163
Please verify email or join us to access premium content!